Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria supplement shows promise for shedding pounds

NCT ID NCT06780007

Disease control Sponsor: Wecare Probiotics Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study tested whether a probiotic called Akkermansia muciniphila Akk11 can help people with obesity lose weight. Over 12 weeks, 106 participants took either the probiotic or a placebo. Researchers measured changes in body mass index (BMI) and also looked at inflammation and metabolism. The goal is to see if this natural supplement could be a safe way to support weight management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Akkermansia muciniphila Akk11 probiotic
What this could lead to
If it works, this could point toward a natural probiotic supplement to help with weight loss and improve metabolic health in people with obesity.
What could go wrong
This is a small, early-stage trial with only 106 participants. The effect may be modest, and results may not apply to everyone. As a dietary supplement, it is not a substitute for lifestyle changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

106 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- 1\) Age 18-65 years old; 2）28≤BMI≤35Kg/m2； 3) Willing and able to comply with the protocol during the study period, and be able to cooperate with the completion of various examinations during the trial. Written informed consent is provided prior to entry into study screening, and the patient has understood that the study can be withdrawn at any time from the study without any loss Exclusion Criteria: 1. Pregnant or lactating women, in the reproductive period and not taking contraceptive measures; 2. Oral antibiotics in the past 1 month prior to enrollment; 3. No use of probiotic prebiotic products before 3 weeks of intervention; 4. people without a fitness fat loss program or history of gastric surgery during the intervention period; 5. Patients with severe gastrointestinal diseases; 6. Those who are known to be allergic to synbiotics or similar products; 7. Patients with no self-awareness and those with mental abnormalities; 8. Have a history of organ transplantation or malignant tumor disease; 9. Concurrent use of other experimental drugs or in other clinical trials; 10. Have a history of alcohol, tobacco and other drug abuse; 11. Those who are expected to be unable to complete the magnetic resonance examination; 12. Combined with serious medical diseases or conditions: such as clinically serious (i.e., active) cardiac disease, severe, uncontrolled medical diseases and infections, severe uncontrollable digestive disorders, severe electrolyte disorders, active disseminated intravascular coagulation, major organ failure, such as decompensated heart, pulmonary, hepatic, renal failure, peripheral neuropathy symptoms, etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 28≤bmi≤35KG/M2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

28≤bmi≤35KG/M2

Contacts and locations

Locations

  • The First Affiliated Hospital, the Air Force Medical University

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.